21 research outputs found
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
IMPORTANCE Most patients with hepatocellular carcinoma (HCC) are diagnosed with
advanced disease not eligible for potentially curative therapies; therefore, new treatment
options are needed. Combining nivolumab with ipilimumab may improve clinical outcomes
compared with nivolumab monotherapy.
OBJECTIVE To assess efficacy and safety of nivolumab plus ipilimumab in patients with
advanced HCC who were previously treated with sorafenib.
DESIGN, SETTING, AND PARTICIPANTS CheckMate 040 is a multicenter, open-label,
multicohort, phase 1/2 study. In the nivolumab plus ipilimumab cohort, patients were
randomized between January 4 and September 26, 2016. Treatment group information was
blinded after randomization. Median follow-up was 30.7 months. Data cutoff for this analysis
was January 2019. Patients were recruited at 31 centers in 10 countries/territories in Asia,
Europe, and North America. Eligible patients had advanced HCC (with/without hepatitis B or
C) previously treated with sorafenib. A total of 148 patients were randomized (50 to arm A
and 49 each to arms B and C).
INTERVENTIONS Patients were randomized 1:1:1 to either nivolumab 1 mg/kg plus ipilimumab 3
mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks
(arm A); nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, administered every 3 weeks (4 doses),
followed by nivolumab 240 mg every 2 weeks (arm B); or nivolumab 3 mg/kg every 2 weeks
plus ipilimumab 1 mg/kg every 6 weeks (arm C).
MAIN OUTCOMES AND MEASURES Coprimary end points were safety, tolerability, and objective
response rate. Duration of response was also measured (investigator assessed with the
Response Evaluation Criteria in Solid Tumors v1.1).
RESULTS Of 148 total participants, 120 were male (81%). Median (IQR) age was 60
(52.5-66.5). At data cutoff (January 2019), the median follow-up was 30.7 months (IQR,
29.9-34.7). Investigator-assessed objective response rate was 32% (95% CI, 20%-47%) in
arm A, 27% (95% CI, 15%-41%) in arm B, and 29% (95% CI, 17%-43%) in arm C. Median
(range) duration of response was not reached (8.3-33.7+) in arm A and was 15.2 months
(4.2-29.9+) in arm B and 21.7 months (2.8-32.7+) in arm C. Any-grade treatment-related
adverse events were reported in 46 of 49 patients (94%) in arm A, 35 of 49 patients (71%) in
arm B, and 38 of 48 patients (79%) in arm C; there was 1 treatment-related death (arm A;
grade 5 pneumonitis).
CONCLUSIONS AND RELEVANCE In this randomized clinical trial, nivolumab plus ipilimumab
had manageable safety, promising objective response rate, and durable responses. The arm A
regimen (4 doses nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks then nivolumab
240 mg every 2 weeks) received accelerated approval in the US based on the results of this
study.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0165887
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Background & Aims: Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable responses, manageable safety, and increased survival in patients with advanced hepatocellular carcinoma (HCC). In our retrospective analysis, we studied the immunobiology and potential associations between biomarkers and outcomes with nivolumab in HCC. Methods: Fresh and archival tumour samples from dose-escalation and dose-expansion phases of the CheckMate 040 trial were analysed by immunohistochemistry and RNA sequencing to assess several inflammatory gene expression signatures, including CD274 (PD-ligand 1 [PD-L1]), CD8A, LAG3, and STAT1. Biomarkers were assessed for association with clinical outcomes (best overall response by blinded independent central review per RECIST v1.1 and overall survival [OS]). Results: Complete or partial tumour responses were observed in PD-L1-positive and PD-L1-negative patients treated with nivolumab monotherapy. Median OS was 28.1 (95% CI 18.2-n.a.) vs. 16.6 months (95% CI 14.2-20.2) for patients with tumour PD-L1 >= 1% vs. <1% (p = 0.03). Increased CD3 and CD8 showed a non-significant trend towards improved OS (both p = 0.08), and macrophage markers were not associated with OS. Tumour PD-1 and PD-L1 expression were associated with improved OS (p = 0.05 and p = 0.03, respectively). An inflammatory gene signature consisting of 4 genes was associated with improved objective response rate (p = 0.05) and OS (p = 0.01). Conclusions: PD-1 and PD-L1 expression, biomarkers of inflammation, and inflammatory gene signatures trended with improved survival and response. While further confirmation within a larger phase III trial is needed to evaluate predictive value of these biomarkers, these exploratory analyses suggest that anti-tumour immune response may play a role in the treatment benefit of nivolumab in HCC. Lay summary: Certain tests may be used to provide a picture of how a tumour is escaping the immune system, allowing it to continue to grow and create more tumours. Therapies such as nivolumab are designed to help the immune system fight the tumour. These tests may be used to determine how effective such therapies will be in the treatment of advanced liver cancer. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two
Background
The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd.
Methods
We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background.
Results
First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001).
Conclusions
In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
Background: Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced cohorts of CheckMate 040 are presented here.
Patients and methods: Patients received nivolumab monotherapy at dose levels of 0.1-10.0 mg/kg (dose-escalation phase) or 3 mg/kg (dose-expansion phase) every 2 weeks until disease progression or unacceptable toxicity. Primary endpoints were safety and tolerability (dose escalation), and objective response rate (ORR) by blinded independent central review (BICR) and by investigator per RECIST version 1.1 (dose expansion).
Results: Eighty sorafenib-naive and 154 sorafenib-experienced patients were treated. Minimum follow-up in both groups was 60 months. ORR per BICR was 20% (95% CI 12-30) and 14% (95% CI 9-21) in the sorafenib-naive and sorafenib-experienced groups, respectively. Responses occurred regardless of HCC etiology or baseline tumor cell programmed death ligand 1 (PD-L1) expression levels. Median overall survival (OS) was 26.6 months (95% CI 16.6-30.6) and 15.1 months (95% CI 13.0-18.2) in sorafenib-naive and sorafenib-experienced patients, respectively. The 3-year OS rates were 28% in the sorafenib-naive and 20% in the sorafenib-experienced group; 5-year OS rates were 14% and 12%, respectively. No new safety signals were identified; grade 3/4 treatment-related adverse events were observed in 33% and 21% in the sorafenib-naive and sorafenib-experienced patients, respectively. Biomarker analyses showed that baseline PD-L1 expression ≥1% was associated with higher ORR and longer OS compared with PD-L1 <1%. In the sorafenib-naive group, patients with OS ≥3 years exhibited higher baseline CD8 T-cell density compared with those with OS <1 year.
Conclusion: With 5 years of follow-up, nivolumab monotherapy continued to provide durable clinical benefit with manageable safety in sorafenib-naive and sorafenib-experienced patients with aHCC
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
20sireservedPurpose: Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and pharmacodynamic activity of urelumab, including the dose selected for ongoing development in patients with advanced solid tumors and lymphoma.Experimental Design: A total of 346 patients with advanced cancers who had progressed after standard treatment received at least one dose of urelumab in one of three dose-escalation, monotherapy studies. Urelumab was administered at doses ranging from 0.1 to 15 mg/kg. Safety analyses included treatmentrelated and serious adverse events (AEs), as well as treatment-related AEs leading to discontinuation and death, with a focus on liver function test abnormalities and hepatic AEs.Results: Urelumab doses between 1 and 15 mg/kg given every 3 weeks resulted in a higher frequency of treatment-related AEs than 0.1 or 0.3 mg/kg every 3 weeks. Dose was the single most important factor contributing to transaminitis development, which was more frequent and severe at doses >= 1 mg/kg. At the MTD of 0.1 mg/kg every 3 weeks, urelumab was relatively well tolerated, with fatigue (16%) and nausea (13%) being the most common treatment-related AEs, and was associated with immunologic and pharmacodynamic activity demonstrated by the induction of IFN-inducible genes and cytokines.Conclusions: Integrated evaluation of urelumab safety data showed significant transaminitis was strongly associated with doses of >= 1 mg/kg. However, urelumab 0.1 mg/kg every 3 weeks was demonstrated to be safe, with pharmacodynamic activity supporting continued clinical evaluation of this dose as monotherapy and in combination with other immuno-oncology agents. (C) 2016 AACR.mixedSegal N.H.; Logan T.F.; Hodi F.S.; McDermott D.; Melero I.; Hamid O.; Schmidt H.; Robert C.; Chiarion-Sileni V.; Ascierto P.A.; Maio M.; Urba W.J.; Gangadhar T.C.; Suryawanshi S.; Neely J.; Jure-Kunkel M.; Krishnan S.; Kohrt H.; Sznol M.; Levy R.Segal, N. H.; Logan, T. F.; Hodi, F. S.; Mcdermott, D.; Melero, I.; Hamid, O.; Schmidt, H.; Robert, C.; Chiarion-Sileni, V.; Ascierto, P. A.; Maio, M.; Urba, W. J.; Gangadhar, T. C.; Suryawanshi, S.; Neely, J.; Jure-Kunkel, M.; Krishnan, S.; Kohrt, H.; Sznol, M.; Levy, R
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Background & Aims: Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable responses, manageable safety, and increased survival in patients with advanced hepatocellular carcinoma (HCC). In our retrospective analysis, we studied the immunobiology and potential associations between biomarkers and outcomes with nivolumab in HCC. Methods: Fresh and archival tumour samples from dose-escalation and dose-expansion phases of the CheckMate 040 trial were analysed by immunohistochemistry and RNA sequencing to assess several inflammatory gene expression signatures, including CD274 (PD-ligand 1 [PD-L1]), CD8A, LAG3, and STAT1. Biomarkers were assessed for association with clinical outcomes (best overall response by blinded independent central review per RECIST v1.1 and overall survival [OS]). Results: Complete or partial tumour responses were observed in PD-L1-positive and PD-L1-negative patients treated with nivolumab monotherapy. Median OS was 28.1 (95% CI 18.2-n.a.) vs. 16.6 months (95% CI 14.2-20.2) for patients with tumour PD-L1 >= 1% vs. <1% (p = 0.03). Increased CD3 and CD8 showed a non-significant trend towards improved OS (both p = 0.08), and macrophage markers were not associated with OS. Tumour PD-1 and PD-L1 expression were associated with improved OS (p = 0.05 and p = 0.03, respectively). An inflammatory gene signature consisting of 4 genes was associated with improved objective response rate (p = 0.05) and OS (p = 0.01). Conclusions: PD-1 and PD-L1 expression, biomarkers of inflammation, and inflammatory gene signatures trended with improved survival and response. While further confirmation within a larger phase III trial is needed to evaluate predictive value of these biomarkers, these exploratory analyses suggest that anti-tumour immune response may play a role in the treatment benefit of nivolumab in HCC. Lay summary: Certain tests may be used to provide a picture of how a tumour is escaping the immune system, allowing it to continue to grow and create more tumours. Therapies such as nivolumab are designed to help the immune system fight the tumour. These tests may be used to determine how effective such therapies will be in the treatment of advanced liver cancer. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
LONGER-TERM FOLLOW-UP OF A PHASE 2 STUDY (CHECKMATE 063) OF NIVOLUMAB IN PATIENTS WITH ADVANCED REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
IMPORTANCE Most patients with hepatocellular carcinoma (HCC) are diagnosed with
advanced disease not eligible for potentially curative therapies; therefore, new treatment
options are needed. Combining nivolumab with ipilimumab may improve clinical outcomes
compared with nivolumab monotherapy.
OBJECTIVE To assess efficacy and safety of nivolumab plus ipilimumab in patients with
advanced HCC who were previously treated with sorafenib.
DESIGN, SETTING, AND PARTICIPANTS CheckMate 040 is a multicenter, open-label,
multicohort, phase 1/2 study. In the nivolumab plus ipilimumab cohort, patients were
randomized between January 4 and September 26, 2016. Treatment group information was
blinded after randomization. Median follow-up was 30.7 months. Data cutoff for this analysis
was January 2019. Patients were recruited at 31 centers in 10 countries/territories in Asia,
Europe, and North America. Eligible patients had advanced HCC (with/without hepatitis B or
C) previously treated with sorafenib. A total of 148 patients were randomized (50 to arm A
and 49 each to arms B and C).
INTERVENTIONS Patients were randomized 1:1:1 to either nivolumab 1 mg/kg plus ipilimumab 3
mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks
(arm A); nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, administered every 3 weeks (4 doses),
followed by nivolumab 240 mg every 2 weeks (arm B); or nivolumab 3 mg/kg every 2 weeks
plus ipilimumab 1 mg/kg every 6 weeks (arm C).
MAIN OUTCOMES AND MEASURES Coprimary end points were safety, tolerability, and objective
response rate. Duration of response was also measured (investigator assessed with the
Response Evaluation Criteria in Solid Tumors v1.1).
RESULTS Of 148 total participants, 120 were male (81%). Median (IQR) age was 60
(52.5-66.5). At data cutoff (January 2019), the median follow-up was 30.7 months (IQR,
29.9-34.7). Investigator-assessed objective response rate was 32% (95% CI, 20%-47%) in
arm A, 27% (95% CI, 15%-41%) in arm B, and 29% (95% CI, 17%-43%) in arm C. Median
(range) duration of response was not reached (8.3-33.7+) in arm A and was 15.2 months
(4.2-29.9+) in arm B and 21.7 months (2.8-32.7+) in arm C. Any-grade treatment-related
adverse events were reported in 46 of 49 patients (94%) in arm A, 35 of 49 patients (71%) in
arm B, and 38 of 48 patients (79%) in arm C; there was 1 treatment-related death (arm A;
grade 5 pneumonitis).
CONCLUSIONS AND RELEVANCE In this randomized clinical trial, nivolumab plus ipilimumab
had manageable safety, promising objective response rate, and durable responses. The arm A
regimen (4 doses nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks then nivolumab
240 mg every 2 weeks) received accelerated approval in the US based on the results of this
study.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0165887